Why the study?
Recent FDA approval of colchicine for secondary prevention of atherosclerotic cardiovascular disease raised concerns regarding its anti-healing effects on myocardial tissue post-infarction.
Does colchicine increase the risk of late myocardial rupture in patients with recent myocardial infarction?
Does colchicine increase the risk of late myocardial rupture in patients with recent myocardial infarction?
Colchicine use for post-MI pericarditis may impair myocardial healing and increase the risk of late ventricular free wall rupture, warranting caution in its use following large myocardial infarctions.
Answers are grounded in this paper and cite their sources.
May signal colchicine-related rupture risk post-MI; hypothesis-generating case report that should not change practice.
Colchicine is one of the established drugs of choice for post-myocardial infarction (MI) induced pericarditis, given its anti-inflammatory properties. Recently, colchicine received FDA approval for secondary prevention of atherosclerotic cardiovascular disease, which leads to concerns regarding its anti-healing effects on myocardial tissue post-infarction. We present a case of a suspected colchicine-induced myocardial rupture in an elderly male, who presented with a syncopal episode while on colchicine three weeks after the late presentation of infero-posterior ST-elevation myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Abdullah Mohamed Niyas (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: